Literature DB >> 36169858

Assay of MAO Inhibition by Chromatographic Techniques (HPLC/HPLC-MS).

Tomás Herraiz1.   

Abstract

Monoamine oxidase (MAO) enzymes (MAO A and B) catalyze the oxidative deamination of biogenic amines, neurotransmitters, and xenobiotic amines and contribute to the regulation of the content of these active substances in mammalian organisms. The oxidation of biogenic amines by MAO produces hydrogen peroxide (H2O2) and aldehydes that represent risk factors for oxidative injury. The inhibitors of MAO are useful as antidepressants and neuroprotective agents. Usually, the assays of MAO determine amine deamination products or measure the H2O2 released by using direct spectrophotometric or fluorimetric methods. Direct methods are more prone to interferences and can afford inaccurate results. Those limitations can be avoided by using chromatographic techniques. This work describes a chromatographic method to assay MAO A and MAO B activity by using kynuramine as a nonselective substrate and the subsequent analysis of 4-hydroxyquinoline by RP-HPLC-DAD-fluorescence and mass spectrometry (MS). Alternatively, the assay uses the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin as a substrate of MAO that is oxidized (bioactivated) to neurotoxic pyridinium cations which are analyzed by HPLC. These methods are applied to assess the inhibition of MAO by bioactive β-carboline alkaloids occurring in foods, plants, and biological systems.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); 1-Methyl-4-phenyl-2,3-dihydropyridinium (MPDP+); 4-Hydroxyquinoline; Harman; Hydrogen peroxide (H2O2); Kynuramine; MAO assay; Norharman; RP-HPLC; β-Carbolines

Mesh:

Substances:

Year:  2023        PMID: 36169858     DOI: 10.1007/978-1-0716-2643-6_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  38 in total

Review 1.  Focusing on new monoamine oxidase inhibitors.

Authors:  Adriana Bolasco; Simone Carradori; Rossella Fioravanti
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

Review 2.  The therapeutic potential of monoamine oxidase inhibitors.

Authors:  Moussa B H Youdim; Dale Edmondson; Keith F Tipton
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

3.  Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.

Authors:  G Cohen; R Farooqui; N Kesler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

Review 4.  Structural properties of human monoamine oxidases A and B.

Authors:  Claudia Binda; Andrea Mattevi; Dale E Edmondson
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

Review 5.  Structure and mechanism of monoamine oxidase.

Authors:  D E Edmondson; A Mattevi; C Binda; M Li; F Hubálek
Journal:  Curr Med Chem       Date:  2004-08       Impact factor: 4.530

Review 6.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

7.  New insights into the structures and functions of human monoamine oxidases A and B.

Authors:  D E Edmondson; L DeColibus; C Binda; M Li; A Mattevi
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

Review 8.  Clinical pharmacology of MAO inhibitors: safety and future.

Authors:  Mitsuhiko Yamada; Hajime Yasuhara
Journal:  Neurotoxicology       Date:  2004-01       Impact factor: 4.294

9.  Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease.

Authors:  Jyothi K Mallajosyula; Shankar J Chinta; Subramanian Rajagopalan; David G Nicholls; Julie K Andersen
Journal:  Neurotox Res       Date:  2009-03-05       Impact factor: 3.911

10.  MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

Authors:  Jyothi K Mallajosyula; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Anand Rane; David G Nicholls; Donato A Di Monte; Heather Macarthur; Julie K Andersen
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.